TL;DR
Aging and weight-loss drugs like Wegovy both cost people muscle, the thing that keeps them climbing stairs and getting out of chairs. Two drugs built to protect it now have dates on the calendar. On Nov. 16, Veru presents a new look at enobosarm, a pill, in patients aged 60 and up who took it alongside semaglutide (the drug in Wegovy), focused on how well they kept their physical function. The company says the pill preserved lean mass and function; it has released no figures yet, and the analysis was chosen after the trial ended. Separately, Scholar Rock, which won the first approval for a myostatin-pathway drug in September (myostatin is the body's brake on muscle size), says its next shot, SRK-439, is being tested in healthy volunteers, with first results expected by the end of 2026 and shared in early 2027. Our odds on when a muscle-keeping add-on to weight-loss drugs reaches patients, and the timeline of breakthroughs that leads there, are below the line: subscribe to read them.
Below the line, for paid subscribers: The full story: where it stands, how we got here and what's dated next; our labeled speculation on what it adds up to; and every source.